Roche AG an exclusive worldwide license for an RNAi candidate targeting activin receptor-like kinase 7 (ALK7). The compound deploys Shanghai-based Rona’s extrahepatic delivery platform and is designed ...

Sitryx Therapeutics Ltd. has delivered the first clinical data for a new mechanism of action (MOA) in atopic dermatitis and ...

The activin receptor-like kinase 7 (ALK7) pathway got another vote of confidence as Rona Therapeutics Inc. came to terms with ...

Two phase III successes have delivered validation for Bristol Myers Squibb Co. across two strategically important programs, ...

The Japanese government is seeking to strengthen the country’s global biotech position amid U.S. drug pricing changes and ...

U.S. President Donald Trump signed in the third quarter directly impact the biopharma and med-tech space, one of them has continued to court controversy as the Senate considers the nomination of Heidi ...

Ono Pharmaceutical Co. Ltd. is paying $100 million up front to gain select Asian rights to Biohaven Ltd.’s small-molecule IgG degrader portfolio, including in Japan, South Korea and Taiwan, as it ...

Syntara Ltd. reported additional phase II data supporting development of SNT-4728 as a potential disease-modifying therapy for Parkinson's disease, with patients at high risk of developing the ...

Ono Pharmaceutical Co. Ltd. is paying $100 million up front to gain select Asian rights to Biohaven Ltd.’s small-molecule IgG degrader portfolio, including in Japan, South Korea and Taiwan, as it ...

Global biotech disruptions – U.S. pricing policy, China’s rise and the growing importance of AI and health data – are creating an opening for Japan to use its scientific strengths to develop and ...

Diosynvax Ltd., a spinout of the University of Cambridge, together with partners at the University of Cambridge, University ...

Psychiatric drug discovery is “ready for transformation 2.0,” Roger McIntyre told his audience at the annual congress of the ...